



Baker IDI Research Online

<http://library.bakeridi.edu.au>

This is the postprint version of the work. It is the manuscript that was accepted by the journal following peer review. It does not include the publisher's layout and pagination.

"Petersen KS, Keogh JB, Meikle PJ, Garg ML, Clifton PM. Dietary predictors of arterial stiffness in a cohort with type 1 and type 2 diabetes. Atherosclerosis. 2015;238(2):175-81."

<http://hdl.handle.net/11187/2117>

Dietary predictors of arterial stiffness in a cohort with type 1 and type 2 diabetes

KS Petersen^a, JB Keogh^a, PJ Meikle^b, ML Garg^c, PM Clifton^a

^a*School of Pharmacy and Medical Sciences & Sansom Institute for Health Research, University of South Australia, Adelaide, Australia;* ^b*Baker IDI Heart and Diabetes Institute, Melbourne, Australia;* ^c*Nutraceuticals Research Group, University of Newcastle, Callaghan, Australia.*

Authors

Kristina S Petersen BNutDiet(Hons), Accredited Practicing Dietitian (APD), PhD Candidate, School of Pharmacy and Medical Sciences, University of South Australia, GPO Box 2471 Adelaide SA 5000, Telephone +61 8 8302 1025, Fax +61 8 8302 2389, Email kristina.petersen@mymail.unisa.edu.au

Jennifer B Keogh PhD APD, Associate Professor of Dietetics & Nutrition and Fellow of the South Australian Cardiovascular Research Development Program, School of Pharmacy and Medical Sciences, University of South Australia, GPO Box 2471 Adelaide SA 5000, Telephone +61 8 8302 2579, Fax +61 8 8302 2389, Email jennifer.keogh@unisa.edu.au

Peter J Meikle PhD, Associate Professor, NHMRC Senior Research Fellow and Head Metabolomics Laboratory Baker IDI Heart and Diabetes Institute, 75 Commercial Road, Melbourne VIC 3004, Telephone +61 (0)3 8532 1770, Fax +61 (0)3 8532 1100, Email peter.meikle@bakeridi.edu.au

Manohar L Garg PhD, Professor, Director, Nutraceuticals Research Group and Co-Director, Clinical Nutrition Research Centre, 305C Medical Science Building, University of Newcastle, Callaghan, NSW 2308, Tel: +61 24921 5647, Fax: +61 24921 202, E-mail: manohar.garg@newcastle.edu.au

Peter M Clifton PhD, Professor of Nutrition & NHMRC Principal Research Fellow, School of Pharmacy and Medical Sciences, University of South Australia, GPO Box 2471 Adelaide SA 5000, Telephone +61 8 8462 9702, Fax +61 8 8302 2389, Email peter.clifton@unisa.edu.au

Corresponding author

Peter M Clifton PhD, Professor of Nutrition & NHMRC Principal Research Fellow, School of Pharmacy and Medical Sciences, University of South Australia, GPO Box 2471 Adelaide SA 5000, Telephone +61 8 8462 9702, Fax +61 8 8302 2389, Email peter.clifton@unisa.edu.au

Number of tables/figures= 5

1 ABSTRACT

2 Objective: To determine the dietary predictors of central blood pressure, augmentation index and
3 pulse wave velocity (PWV) in subjects with type 1 and type 2 diabetes.

4 Methods: Participants were diagnosed with type 1 or type 2 diabetes and had PWV and/or pulse
5 wave analysis performed. Dietary intake was measured using the Dietary Questionnaire for
6 Epidemiological Studies Version 2 Food Frequency Questionnaire. Serum lipid species and
7 carotenoids were measured, using liquid chromatography electrospray ionization–tandem mass
8 spectrometry and high performance liquid chromatography, as biomarkers of dairy and vegetable
9 intake, respectively. Associations were determined using linear regression adjusted for potential
10 confounders.

11 Results: PWV (n=95) was inversely associated with reduced fat dairy intake ($\beta=-0.01$; 95% CI -0.02, -
12 0.01; $p=0<0.05$) in particular yoghurt consumption ($\beta=-0.04$; 95% CI -0.09, -0.01; $p=0<0.05$) after
13 multivariate adjustment. Total vegetable consumption was negatively associated with PWV in the
14 whole cohort after full adjustment ($\beta = -0.04$; 95% CI -0.07,-0.01; $p<0.05$). Individual lipid species,
15 particularly those containing 14:0, 15:0, 16:0, 17:0 and 17:1 fatty acids, known to be of ruminant
16 origin, in lysophosphatidylcholine, cholesterol ester, diacylglycerol, phosphatidylcholine,
17 sphingomyelin and triacylglycerol classes were positively associated with intake of full fat dairy, after
18 adjustment for multiple comparisons. However, there was no association between serum lipid
19 species and PWV. There were no dietary predictors of central blood pressure or augmentation index
20 after multivariate adjustment.

21 Conclusion: In this cohort of subjects with diabetes reduced fat dairy intake and vegetable
22 consumption were inversely associated with PWV. The lack of a relationship between serum lipid
23 species and PWV suggests that the fatty acid composition of dairy may not explain the beneficial
24 effect.

25 Keywords: Diabetes, arterial stiffness, pulse wave velocity, dairy, lipidomics, carotenoids

26 INTRODUCTION

27 The number of people with diabetes is projected to be 7.7% worldwide by 2030, an increase of 54%
28 since 2010 [1]. Individuals with type 1 and type 2 diabetes have approximately double the risk of
29 cardiovascular disease (CVD) compared to the general population [2, 3]. Dietary intake is a
30 modifiable risk factor for CVD with studies showing that better dietary quality reduces the risk of
31 CVD [4, 5].

32 Arterial stiffness, which can be measured by carotid femoral pulse wave velocity (PWV) and
33 augmentation index, is a predictor of CVD [6, 7]. A meta-analysis of individual participant data from
34 17 studies (17 635 subjects) showed that PWV independently predicted CVD and CVD mortality such
35 that per 1 standard deviation increase in PWV the hazard ratio was 1.30 (95% CI 1.18, 1.43) and 1.28
36 (95% CI 1.15, 1.43), respectively, after adjustment for established risk factors. Furthermore, the
37 addition of PWV to conventional Framingham risk factors improved 10 year CVD risk prediction by
38 13% in those at intermediate risk of CVD [7]. Elevated central blood pressure and a larger
39 augmentation index have also been shown to increase the risk of a cardiovascular event [6].

40 The SEARCH for Diabetes in Youth Study, involving children aged ≥ 10 years with type 1 diabetes,
41 showed that a dietary pattern, determined by reduced rank regression, high in sugar sweetened and
42 diet beverages, eggs, potatoes, high fat meat and low in dairy was associated with higher
43 augmentation index and PWV; however the relationship with PWV did not persist after adjustment
44 for cofounders [8]. Epidemiological studies conducted in cohorts without diabetes suggest that fruit
45 and vegetables [9-11] and dairy [12, 13] may be inversely associated with PWV. The aim of this
46 study is to determine the dietary predictors of central blood pressure, augmentation index and PWV
47 in subjects with type 1 and type 2 diabetes.

48

49 METHODS

50 Study methods

51 This is a cross-sectional study of the association between dietary intake and arterial stiffness in
52 subjects with type 1 and type 2 diabetes. One hundred and fifty subjects were recruited by public
53 advertisement between August 2012 and December 2013. Subjects eligible for inclusion were adults
54 (age >18 years) with diagnosed type 1 or type 2 diabetes for any duration managed with diet, oral
55 hypoglycaemic agents (OHA) and/or insulin. Subjects were excluded if they had cancer, unstable CVD
56 requiring intervention, heart failure, significant renal impairment (eGFR <30ml/min) or liver disease.
57 This study includes data from participants who had PWV (n=95) and/or pulse wave analysis
58 measurements (n=111) performed. Thirty nine- participants did not have PWV or pulse wave
59 analysis performed because the equipment was not available and PWV data were available for only
60 95 participants because of technical difficulty performing the measurement due to obesity. Ethics
61 approval was obtained from the University of South Australia Human Research Ethics Committee
62 and the trial was registered with the Australian New Zealand Clinical Trials Registry
63 (ACTRN12612001052820).

64 Subjects attended the clinic after an overnight fast. Anthropometric measurements, pulse wave
65 analysis, PWV and blood pressure were performed by one operator and a blood sample was taken.
66 Participants completed the online version of the Dietary Questionnaire for Epidemiological Studies
67 Version 2 Food Frequency Questionnaire (DQES v2 FFQ) to determine habitual dietary intake.

68

69 Anthropometric measurements

70 Height was measured using a stadiometer (SECA, Hamburg, Germany) to the nearest 0.1cm while
71 barefoot or in flat footwear. Weight was measured to the nearest 0.05kg using calibrated electronic

72 scales (SECA, Hamburg, Germany) while the participants were barefoot or in light footwear and
73 wearing light clothing.

74

75 Blood pressure

76 Clinic brachial blood pressure was measured using an automated sphygmomanometer (SureSigns
77 VS3; Philips, North Ryde, Australia) once the participant had been seated for 5 minutes. A normal
78 sleeve (16 x 52cm) was used for an arm circumference of 24-32cm and a large sleeve (16 x 70cm) for
79 an arm circumference of 32-42cm. A minimum of four consecutive readings were taken at 1 minute
80 intervals while subjects were sitting quietly and alone. The first reading was discarded and the
81 following three consistent measurements i.e. systolic blood pressure within a range of 10mmHg,
82 were used [14].

83

84 Pulse wave analysis

85 A SphygmoCor[®] XCEL (AtCor Medical, West Ryde, Australia) was used to perform pulse wave analysis
86 as previously described [15]. Briefly, a cuff was placed over the brachial artery on the right arm to
87 measure central blood pressure, augmentation index and augmented pressure. A normal sleeve (16
88 x 52cm) was used for an arm circumference of 23-33cm and a large sleeve (16 x 70cm) for an arm
89 circumference of 31-40cm. After the participants had been quietly resting for 5 minutes, 3
90 consecutive measurements were taken. The coefficient of variation (CV) was 11% (n=5).

91

92 Pulse wave velocity

93 A SphygmoCor[®] XCEL (AtCor Medical, West Ryde, Australia) was used to measure right carotid
94 femoral PWV as previously described [15]. Three measurements were performed and all of the
95 measurements were taken by one operator with a CV of 4.2% (n=28).

96

97 Laboratory analysis

98 Serum total cholesterol, HDL cholesterol, triglycerides, C reactive protein (CRP) and glucose were
99 measured using a Konelab 20XTi automatic analyser (Thermo Electron Corporation, Louisville, CO,
100 USA) with reagents from Thermo Fisher Scientific (Melbourne, Australia). LDL cholesterol was
101 calculated using the Friedewald formula ((total cholesterol - HDL cholesterol) – (triglycerides x 0.45))
102 [16]. Subjects with a serum CRP >10mg/L were excluded from the analysis. Serum carotenoids were
103 measured by high performance liquid chromatography according to a previously published protocol
104 [17]. Lipid analysis was performed by liquid chromatography, electrospray ionization–tandem mass
105 spectrometry as previously published [18]. Briefly, 333 individual lipid species from 25 classes were
106 measured and the median intra assay CV was 8%.

107

108 Dietary analysis

109 Habitual dietary intake was measured using the electronic version of the DQES v2 FFQ. This FFQ has
110 been found to have relatively good agreement with a 3 day weight food record [19]. It classifies
111 more than two thirds of subjects within one quintile, for all nutrients, compared with a 3 day
112 weighed food record [20].

113

114 Statistical analysis

115 Data are presented as mean \pm standard deviation or median (interquartile range) depending on the
116 distribution. Data were checked for normality using Shapiro-Wilk and Kolmogorov-Smirnov values.
117 Pearson's correlation was used to determine univariate relationships and stepwise multivariate
118 linear regression was used to determine predictors of central blood pressure, augmentation index
119 and PWV. Variables that were correlated ($p < 0.1$) with the variable of interest in Pearson's
120 correlation were entered into a stepwise linear regression to determine predictors. Linear regression
121 analysis was adjusted for predictors identified in the stepwise linear regression and outliers (± 2
122 standard deviations) were removed. To determine the level of under-reporting the Schofield
123 equation was used to calculate Basal Metabolic Rate [21] and the Goldberg cut-off was applied [22].
124 Significant under-reporting was observed. Therefore intake is reported as a percentage of total
125 energy intake or units per 1000kJ. Serum carotenoids and serum lipid concentrations were
126 normalised to their respective interquartile ranges to account for the variation in relative abundance
127 in serum. Therefore the β - coefficients obtained correspond to a change in the outcome measure
128 associated with an increase in the serum carotenoid or lipid concentration relative to the
129 interquartile range. The association between reported dairy intake from the FFQ and lipids was
130 investigated using linear regression adjusted for age, sex, type of diabetes and BMI. P values were
131 corrected for multiple comparisons using the Benjamini Hochberg approach [18]. Analysis was
132 performed using SPSS (version 19, 2010, SPSS Inc, Chicago, IL). Statistical significance was set at
133 $p < 0.05$.

134

135 RESULTS

136 Subjects were 111 adults with diagnosed type 1 or type 2 diabetes, see Table 1. The subjects with
137 type 2 diabetes were significantly older than those with type 1 diabetes (59 ± 11 vs. 42 ± 15 years;
138 $p = 0.0001$). There was no difference in weight, BMI or peripheral blood pressure by diabetes type.
139 HDL cholesterol was higher in the subjects with type 1 diabetes (1.5 ± 0.4 vs. 1.1 ± 0.3 mmol/L;
140 $p = 0.0001$), but there was no difference in total cholesterol, LDL cholesterol or triglycerides. Fasting

141 glucose was significantly higher in the subjects with type 1 diabetes (12.2 ± 3.8 vs. 7.8 ± 2.6 mmol/L;
 142 $p= 0.0001$), but there was no difference in HbA1c. Forty six (46%) of the subjects with type 2
 143 diabetes were concurrently prescribed an anti-hypertensive and lipid lowering medication, and a
 144 further 18 subjects were prescribed either an anti-hypertensive or lipid lowering medication. Twenty
 145 two subjects with type 2 diabetes were not taking any medication to control their diabetes, 56 were
 146 taking an OHA and 3 were prescribed insulin, 20 subjects were taking an OHA and insulin. One
 147 subject with type 1 diabetes was prescribed anti-hypertensive and lipid lowering medication and 3
 148 subjects were prescribed an antihypertensive medication. All the subjects with type 1 diabetes were
 149 prescribed insulin with no other concurrent hypoglycaemic agents.

150 **Table 1: Subject characteristics**

Characteristic	Whole cohort (n=111)	Type 1 diabetes (n=10)	Type 2 diabetes (n=101)	P value [^]
Age (years)	58 ± 12	42 ± 15	59 ± 11	0.0001
Weight (kg)	100.3 ± 21.6	98.8 ± 29.5	100.4 ± 20.8	>0.05
Height (m)	1.7 ± 0.1	1.72 ± 0.1	1.72 ± 0.1	>0.05
BMI (kg/m ²)	34.0 ± 6.9	34.0 ± 11.1	34.0 ± 6.4	>0.05
Sex, male	66 (60)	4 (40)	62 (61)	>0.05
Diagnosed with diabetes (years)	9.3 ± 8.7	24.9 ± 9.2	7.7 ± 7.0	0.0001
Smoking (pack years)	9.8 ± 15.5	1.0 ± 2.0	10.7 ± 15.9	0.057
Peripheral systolic blood pressure (mmHg)	129 ± 14	130 ± 16	129 ± 14	>0.05
Peripheral diastolic blood pressure (mmHg)	73 ± 10	70 ± 13	73 ± 10	>0.05
Peripheral mean arterial	91 ± 9	90 ± 11	91 ± 9	>0.05

pressure (mmHg)				
Peripheral pulse pressure (mmHg)	56 ± 14	60 ± 19	56 ± 13	>0.05
Central systolic blood pressure (mmHg)	127 ± 15	122±17	127±15	>0.05
Central diastolic blood pressure (mmHg)	83 ± 10	81±12	84±10	>0.05
Central mean arterial pressure (mmHg)	101 ± 11	98±12	101±11	>0.05
Central pulse pressure (mmHg)	43 ± 12	41±18	44±12	>0.05
Central augmented pressure (mmHg)	9 ± 5	8±6	9±5	>0.05
Augmentation index (%)	20.4 ± 8.3	16.7±8.2	20.7±8.3	>0.05
Pulse wave velocity (m/s)	9.6 ± 1.8	8.2±1.5	9.7±1.8	<0.05
Total cholesterol (mmol/L)	4.2 ± 1.1	4.4 ± 1.4	4.1 ± 1.1	>0.05
HDL cholesterol (mmol/L)	1.1 ± 0.3	1.5 ± 0.4	1.1 ± 0.3	0.001
LDL cholesterol (mmol/L)	2.4 ± 0.9	2.6 ± 1.2	2.4 ± 0.9	>0.05
Triglycerides (mmol/L)	1.4 ± 1.3	0.8 ± 0.3	1.5 ± 1.3	>0.05
Glucose (mmol/L)	8.2 ± 3.0	12.2 ± 3.8	7.8 ± 2.6	0.0001
HbA1c (mmol/mol)	57 ± 16	59 ± 13	57 ± 17	>0.05
CRP (mg/L)	2.6 ± 2.4	2.6 ± 2.4	2.6 ± 2.4	>0.05
Prescribed anti-hypertensive medication	68 (61)	4 (40)	64 (63)	>0.05
Prescribed lipid lowering medication	65 (59)	1 (10)	64 (63)	0.001

Diabetes treatment				0.0001
None	22 (20)	0 (0)	22 (22)	
OHA	56 (50)	0 (0)	56 (55)	
Insulin	13 (12)	10 (100)	3 (3)	
OHA + Insulin	20 (18)	0 (0)	20 (20)	

151 Data presented as mean \pm standard deviation; ^type 1 vs. type 2

152

153 Table 1 shows central blood pressure, augmentation index and PWV data for the whole cohort.

154 There was no difference in central blood pressure or augmentation index by diabetes type. PWV was
 155 significantly higher in subjects with type 2 diabetes compared to those with type 1 diabetes ($9.7 \pm$
 156 1.8 vs. 8.2 ± 1.5 m/s; $p < 0.05$), but this was no longer significant after age adjustment.

157 There was no statistically significant difference in dietary intake by diabetes type, therefore data is
 158 presented for the whole cohort, see Table 2. The median macronutrient composition was 21%, 36%,
 159 14% and 40% of total energy from protein, fat, saturated fat and carbohydrate, respectively. Dietary
 160 intake of the major food groups is presented in Table 3. Serum α - carotene ($r = 0.31$; $p = 0.001$) and β -
 161 carotene ($r = 0.23$; $p < 0.05$), expressed as interquartile normalised concentration were significantly
 162 associated with vegetable intake (g/1000kJ) derived from the FFQ and serum lycopene
 163 concentration approached statistical significance ($r = 0.19$; $p = 0.053$). There were no correlations
 164 between total carotenoids, lutein/ zeaxanthin and β -cryptoxanthin and dietary intake.

165 **Table 2: Nutrient intake as reported in the FFQ**

Nutrient intake	Value
Energy	6837 (5601, 9074)
Protein (g/d)	87 (66,110)
% E protein	21 (18, 23)

Total fat (g/d)	65 (51, 91)
% E total fat	36 (33, 40)
Saturated fat (g/d)	24 (19, 34)
% E saturated fat	14 (12, 15)
Monounsaturated fat (g/d)	24 (18, 33)
% E monounsaturated fat	13 (11, 15)
Polyunsaturated fat (g/d)	11 (8, 14)
% E polyunsaturated fat	6 (5, 7)
Carbohydrate (g/d)	158 (135, 208)
% E carbohydrate	40 (37, 44)
Sugar (g/d)	75 (56, 94)
Fibre (g/d)	20 (16, 26)
Sodium (mg/d)	2199 (1693, 2953)
Potassium (mg/d)	2742 (2190, 3394)
Alcohol (g/d)	2 (0, 14)

166 Data presented as median (interquartile range)

167 **Table 3: Dietary intake by food group as reported in the FFQ**

Dietary intake	g/d	g/1000kJ
Total breads and cereals	188 (137, 281)	26 (21, 35)
Breakfast cereal	18 (4, 38)	2 (1, 6)
Bread	60 (53, 90)	9 (6, 13)
Pasta/rice	58 (32, 109)	8 (5, 14)
Total vegetables/ legumes	140 (108, 206)	22 (14, 30)

Vegetables	135 (103, 197)	20 (12, 28)
Legumes	7 (3, 13)	1 (0,2)
Total fruit	245 (124, 337)	33 (19, 46)
Fresh fruit	181 (97, 276)	25 (12, 39)
Canned fruit	5 (1, 14)	1 (0, 2)
Juice	8 (0, 53)	1 (0, 6)
Total dairy	387 (244, 477)	47 (31, 76)
Milk	375 (200, 377)	39 (25, 63)
Yoghurt	41 (10, 73)	5 (1, 12)
Cheese	8 (4, 15)	1 (1, 2)
<i>Reduced fat dairy</i>	299 (67, 448)	42 (10, 73)
Milk	200 (0, 375)	32 (0, 62)
Yoghurt	31 (0, 73)	4 (1, 11)
Cheese	0 (0, 5)	0 (0, 1)
<i>Full fat dairy</i>	9 (3, 20)	1 (0, 3)
Milk	0 (0, 4)	0 (0, 1)
Yoghurt	0 (0, 0)	0 (0, 0)
Cheese	8 (2, 14)	1 (0, 2)
Total meats and alternatives	190 (120, 242)	25 (20, 30)
Red meat	52 (27, 105)	8 (5, 13)
Processed meat	20 (10, 34)	3 (1, 4)
Chicken	31 (19, 51)	4 (3, 6)
Fish	27 (15, 47)	4 (2, 7)
Tofu	0 (0, 2)	0 (0, 1)
Nuts	7 (1, 13)	1 (0, 1)

Eggs	13 (13, 34)	2 (1, 4)
Total extra foods	140 (71, 307)	19 (12, 35)

168 Data presented as median (interquartile range)

169

170 Many lipid species, expressed as interquartile normalised concentration, were positively associated
171 with total full fat dairy intake (g/day), after adjustment for multiple comparisons (Table 4). Individual
172 lipids from the following classes were positively associated with intake of full fat dairy after
173 adjustment for multiple comparisons lysophosphatidylcholine (LPC14:0, LPC15:0, LPC17:1),
174 cholesterol ester (CE14:0, CE15:0), diacylglycerol (DG16:0/20:0), phosphatidylcholine (PC29:0,
175 PC30:0, PC31:0, PC31:1, PC33:0, PC33:1, PC33:3, PC35:0), sphingomyelin (SM31:1, SM32:0) and
176 triacylglycerol (TG14:0/17:0/18:1, TG15:0/16:0/18:1, TG16:0/16:0/16:0, TG16:0/16:1/17:0,
177 TG16:0/17:0/18:0). Many of these associations were also evident for full fat milk; very few
178 associations were observed with cheese consumption. There were no significant associations found
179 between the lipid species and intake of total or reduced fat dairy, after adjustment for multiple
180 comparisons. When dairy intake in grams per 1000kJ was examined many of the same associations
181 were evident (data not shown).

182 **Table 4: Linear regression of serum lipid species against dairy consumption reported in the FFQ,**
183 **adjusted for age, sex, BMI and type of diabetes.**

Dietary intake	B- coefficient (95% CI)	P value	P value corrected [^]
Total dairy			
Nil significant			
Total full fat dairy			
CE 14:0	50.31 (20.05, 80.58)	0.001	0.029

CE 15:0	77.15 (44.77, 109.52)	<0.001	<0.01
DG 16:0/20:0	33.75 (17.26, 50.25)	<0.001	0.006
LPC 14:0	66.97 (26.91, 107.04)	0.001	0.029
LPC 15:0	71.96 (32.84, 111.08)	<0.001	0.016
LPC 17:1	77.12 (29.84, 124.39)	0.002	0.03
PC 29:0	99.62 (64.31, 134.92)	<0.001	<0.01
PC 30:0	55.65 (24.71, 86.60)	0.0006	0.017
PC 31:0	108.09 (71.56, 144.63)	<0.001	<0.01
PC 31:1	78.41 (30.74, 126.07)	0.002	0.03
PC 33:0	109.33 (65.31, 153.35)	<0.001	0.0003
PC 33:1	75.81 (34.08, 117.55)	0.0005	0.017
PC 33:3	78.47 (37.56, 119.39)	0.0002	0.012
PC 35:0	85.94 (43.00, 128.87)	0.0001	0.008
SM 31:1	68.76 (25.29, 112.22)	0.002	0.039
SM 32:0	63.48 (29.09, 97.87)	0.0004	0.016
TG 14:0/17:0/18:1	33.15 (14.00, 52.30)	0.0009	0.025
TG 15:0/16:0/18:1	28.77 (10.25, 47.29)	0.003	0.044
TG 16:0/16:0/16:0	35.77 (13.17, 58.38)	0.002	0.039
TG 16:0/16:1/17:0	32.75 (13.15, 52.35)	0.001	0.029
TG 16:0/17:0/18:0	34.46 (14.00, 54.91)	0.001	0.029
Reduced fat dairy			
Nil significant			

184 ^corrected for multiple comparisons using the Benjamini Hochberg approach (all lipid species were

185 analysed). Only significant associations are shown. CE cholesterol ester; DG diacylglycerol; LPC

186 lysophosphatidylcholine; PC phosphatidylcholine; SM sphingomyelin; TG triacylglycerol

187

188 There was no association with any component of dietary intake and central systolic blood pressure.
189 In univariate analysis inverse associations existed between central diastolic blood pressure and
190 intake (per 1000kJ) of total dairy ($r=-0.21$; $p<0.05$), yoghurt ($r=-0.24$; $p=0.01$), vegetables ($r=-0.2$;
191 $p<0.05$) and potassium ($r=-0.21$; $p<0.05$) and positive associations were observed for rice and pasta
192 ($r=0.21$; $p<0.05$) and takeaway foods ($r=0.23$; $p<0.05$). However, after adjustment for other
193 predictors of central diastolic blood pressure (age and weight) all of these univariate associations
194 were attenuated to non-significance. After multivariate adjustment there were no dietary predictors
195 of central pulse pressure (adjusted for age, sex, time since diabetes diagnosis and anti-hypertensive
196 prescription) or augmentation index (adjusted for age, sex, BMI and total cholesterol). Total
197 vegetable intake (g/1000kJ) was inversely associated with PWV ($\beta = -0.04$; 95% CI -0.07,-0.01;
198 $p<0.05$) after multivariate adjustment (age, BMI, central mean arterial pressure, heart rate and
199 antihypertensive medication prescription). There was no association between serum carotenoids
200 and PWV.

201

202 After adjustment for predictors of PWV (age and central mean arterial pressure) there was a
203 significant inverse relationship between dairy intake and PWV, such that per 100g/1000kJ increase in
204 total dairy intake PWV was 1.1m/s lower (95% CI -2.2, -0.07; $p<0.05$), see Table 5. In addition, there
205 was a significant association observed between total reduced fat dairy consumption and PWV, but
206 no association was evident for full fat dairy. Total and reduced fat yoghurt consumption was
207 inversely associated with PWV. After further adjustment for BMI, heart rate and antihypertensive
208 medication prescription the association with total dairy intake was attenuated to non-significance,
209 see Table 5. However, an inverse relationship remained between PWV and reduced fat dairy in
210 particular yoghurt consumption. Calcium intake was also inversely associated with PWV ($\beta= -0.01$;

211 95% CI -0.02, -0.004; p=0.003). There was no association between any serum lipid species and PWV,
 212 after multivariate adjustment for predictors and adjustment for multiple comparisons.

213 **Table 5: Linear regression of dairy consumption (g/1000kJ) against PWV**

Predictor	Model 1 ²		Model 2 ³	
	β - coefficient (95% CI)	p value	β - coefficient (95% CI)	P value
Pulse wave velocity				
Total dairy ¹	-0.01 (-0.02, -0.01)	0.038	-0.01 (-0.02, 0.01)	0.07
Milk	-0.01 (-0.02, 0.01)	0.13	-0.01 (-0.02, 0.01)	0.33
Cheese	-0.14 (-0.39, 0.11)	0.26	-0.11 (-0.35, 0.13)	0.37
Yoghurt	-0.04 (-0.08, -0.01)	0.046	-0.04 (-0.08, -0.01)	0.03
Reduced fat dairy	-0.01 (-0.02, -0.01)	0.031	-0.01 (-0.02, -0.01)	0.048
Milk	-0.01 (-0.02, 0.01)	0.12	-0.01 (-0.02, 0.01)	0.18
Cheese	-0.37 (-0.87, 0.13)	0.14	-0.34 (-0.82, 0.15)	0.18
Yoghurt	-0.05 (-0.09, -0.01)	0.026	-0.04 (-0.09, -0.01)	0.037
Full fat dairy	0.01 (-0.02, 0.03)	0.82	0.01 (-0.02, 0.03)	0.89
Milk	0.01 (-0.2, 0.04)	0.59	0.01 (-0.02, 0.04)	0.65

Cheese	-0.17 (-0.46, 0.12)	0.25	-0.18 (-0.47, 0.11)	0.21
Yoghurt	0.06 (-0.34, 0.22)	0.66	-0.01 (-0.28, 0.27)	0.99

214 ¹g/1000kJ; ²Adjustment for age and central mean arterial pressure; ³Model 1 + BMI, heart rate and
215 antihypertensive medication prescription

216

217 DISCUSSION

218 In this cohort with type 1 and type 2 diabetes there was an inverse association between reduced fat
219 dairy intake, in particular yoghurt consumption, and PWV, which persisted after multivariate
220 adjustment. Serum lipid species, known to be of ruminant origin, were positively associated with full
221 fat dairy consumption; however there was no association between these lipid species and PWV. In
222 addition, higher vegetable intake was also associated with lower PWV. There were no dietary
223 predictors of central blood pressure or augmentation index identified in this cohort.

224 Previous studies that have investigated the association between dairy intake and PWV have shown
225 mixed results. In the Maine- Syracuse Longitudinal study frequency of overall dairy consumption was
226 inversely associated with PWV [12]. Recio-Rodriguez et al [13] found in a study of healthy Spanish
227 subjects that consumption of low fat dairy was associated with reduced PWV, such that per 100g/d
228 increase PWV was 0.1m/s lower (95% CI -0.18, -0.02; p=0.011). In the study by Recio-Rodreiguez et
229 al consuming whole fat dairy was associated with a 0.1m/s increase (95% CI 0.01, 0.21) in PWV per
230 100g/d [13]. In the Caerphilly Prospective study, involving healthy men, there was no relationship
231 between PWV and dairy consumption [23]. With the exception of the Caerphilly Prospective study,
232 these observational studies did not look at the association between types of dairy products and
233 PWV. In the Caerphilly Prospective study, only cream consumption was associated with PWV, albeit
234 inversely; intake of yoghurt was not included in the analysis. In our study there was an inverse

235 association between PWV and reduced fat dairy intake, but no association was observed with full fat
236 dairy. After multivariate adjustment yoghurt consumption was inversely correlated with PWV,
237 Yoghurt has a hypotensive effect [24] and has also been shown to lower cholesterol [25]. Ivey et al
238 [26] showed that higher yoghurt consumption was associated with lower carotid intima media
239 thickness, a measure of subclinical atherosclerosis. However, an association between yoghurt
240 consumption and PWV has not been previously reported.

241 In this study full fat dairy intake was positively correlated with lipid species containing fatty acids
242 14:0, 15:0 and 17:1, in particular in the lysophosphatidylcholine lipid class. Previously, 15:0 and 17:0
243 fatty acids in lysophosphatidylcholine have been found to correlate with full fat dairy intake [27].
244 The finding that fatty acids from ruminant sources are not associated with PWV, in addition to the
245 lack of an association with full fat dairy, suggests that fatty acids in dairy may not be responsible for
246 the observed beneficial effect. A recent meta-analysis showed that 17:0 was protective against
247 coronary outcomes, with a relative risk for the highest tertile of 17:0 compared with the lowest
248 tertile of 0.77 (95% CI 0.63, 0.93) [28]. Fatty acids 14:0 (RR 0.96; 95% CI 0.83, 1.12) and 15:0 (RR
249 0.94; 95% CI 0.67, 1.32) were also non-significantly associated with a reduced risk of coronary events
250 in this meta-analysis.

251 It is postulated that bioactive peptides in dairy products may account for some of the observed
252 effect by inhibiting angiotensin-I-converting enzyme [29]. Both whey and casein milk proteins have
253 been shown to improve arterial compliance [30, 31]. In addition, the calcium composition of dairy
254 may also explain the effect. A four way cross-over study showed that a high intake of calcium from
255 dairy products in the presence of a high fat intake attenuated the increase in total cholesterol and
256 LDL cholesterol without changing the increase in HDL cholesterol, compared with a high fat, low
257 calcium diet [32]. Similarly, in a study of a high fat diet (50% of total energy) with a milk protein
258 enriched concentration containing 1990mg/10MJ of calcium compared with a control drink
259 (470mg/10MJ of calcium), total cholesterol was 9% lower and LDL cholesterol was 6% lower after

260 the milk protein enriched drink compared with the control treatment, and there was no significant
261 difference in HDL cholesterol [33]. In this analysis we observed an inverse association between
262 calcium intake and PWV.

263 To the authors knowledge there have been no studies that have shown an association between
264 vegetable consumption and PWV. In the Cardiovascular Risk in Young Finns Study total fruit and
265 vegetable consumption, in both childhood and adulthood, was inversely associated with PWV in
266 adulthood [9]. In addition, in a study of rheumatoid arthritis patients augmentation index was
267 inversely associated with frequency of vegetable consumption (-4.2%: 95% CI -7.9, -0.5 with daily
268 vegetable intake compared to less frequently) [34].

269 Previously, epidemiological studies have shown an inverse relationship between lycopene [35, 36],
270 β - carotene [37], β - cryptoxanthin [37] and brachial ankle PWV. However, other studies have
271 reported no effect of carotenoids on arterial stiffness [38]. In this analysis despite an inverse
272 association existing between vegetable intake and PWV, serum carotenoids were not associated
273 with PWV. Studies to date have shown that lycopene, either from supplements or consumption of
274 tomato based products, up to 70mg/week for 2-3 months did not affect PWV [39, 40]. Similarly, a
275 randomised controlled trial, of people at high risk of CVD with habitually low intake of fruit and
276 vegetables, showed that greater intake of fruit and vegetables did not affect PWV after 18 weeks
277 [41]. In this study subjects were randomised to consume +2, +4 and +6 portions/d (above habitual
278 intake), each for 6 weeks, of high flavonoid fruit and vegetables or low flavonoid fruit and
279 vegetables, compared to a control group continuing on their usual diet.

280 In this analysis we showed that reduced fat dairy and vegetable intake were inversely associated
281 with PWV such that per 100g/1000kJ (~half a serve of dairy) increase in reduced fat dairy intake PWV
282 was 0.9m/s lower and per 75g/1000kJ (1 serve of vegetables) increase in vegetable consumption
283 PWV was 2.8m/s lower after full adjustment. A previous meta-analysis of longitudinal studies, with a

284 mean follow-up time of 7.7 years, showed that with a 1m/s lower carotid femoral PWV the risk of a
285 cardiovascular event was reduced by 14% [42].

286 In this study there was no relationship between augmentation index and PWV, which has been
287 previously reported [43]. Augmentation index is not a direct measure of arterial stiffness and is
288 influenced by the timing and magnitude of the wave reflection[44]. In contrast, PWV is a robust
289 measure of arterial stiffness as it is determined by measuring the velocity of the waveform between
290 the carotid and femoral arteries [45]. Previously, it has been shown that in a population with
291 diabetes PWV was elevated compared with healthy controls, however augmentation index was not
292 different [46]. Lacy et al [46] concluded that augmentation index is not a reliable measure of arterial
293 stiffness in people with diabetes. This may explain why we did not see an association between
294 augmentation index and dietary intake, despite seeing correlations with PWV.

295 Limitations of this study include the inclusion of fewer individuals with type 1 diabetes than type 2
296 diabetes and the cross-sectional design. In addition, the use of a FFQ to capture dietary intake is a
297 limitation, although serum carotenoids and lipid species were correlated with reported dietary
298 intake. It is also possible that we did not see an association between serum lipid species and PWV
299 because serum fatty acid composition is not a sensitive marker of dairy intake and the majority of
300 our cohort was consuming reduced fat dairy. A randomised controlled trial showed that when full fat
301 dairy intake was increased by 3 serves per day for 1 month only plasma pentadecanoic acid
302 composition was significantly changed when compared to elimination all of dairy products [47]. The
303 method used to measure augmentation index is based on the averaged transfer function which may
304 blunt the sensitivity of this measure [48].

305

306 CONCLUSION

307 In this cohort of people with type 1 and type 2 diabetes greater consumption of reduced fat dairy
308 and vegetables was associated with less arterial stiffening, as measured by PWV, the gold standard
309 for non-invasively measuring arterial stiffness. However, these results need to be confirmed in a
310 randomised controlled trial. In people with diabetes improving diet quality may reduce the burden
311 of cardiovascular disease by virtue of reducing arterial stiffness.

312

313

314 REFERENCE LIST

- 315 1. Shaw JE, Sicree RA, and Zimmet PZ, *Global estimates of the prevalence of diabetes for 2010*
316 *and 2030*. *Diabetes Res Clin Pract*, 2010. **87**(1): p. 4-14.
- 317 2. Carson AP, Tanner RM, Yun H, Glasser SP, Woolley JM, Thacker EL, Levitan EB, Farkouh ME,
318 Rosenson RS, Brown TM, Howard G, Safford MM, and Muntner P, *Declines in coronary heart*
319 *disease incidence and mortality among middle-aged adults with and without diabetes*. *Ann*
320 *Epidemiol* 2014. **24**(8): p. 581-7.
- 321 3. Juutilainen A, Lehto S, Rönnemaa T, Pyörälä K, and Laakso M, *Similarity of the impact of type*
322 *1 and type 2 diabetes on cardiovascular mortality in middle-aged subjects*. *Diabetes Care*,
323 2008. **31**(4): p. 714-719.
- 324 4. Iqbal R, Anand S, Ounpuu S, Islam S, Zhang X, Rangarajan S, Chifamba J, Al-Hinai A, Keltai M,
325 Yusuf S, and on behalf of the INTERHEART Study Investigators, *Dietary Patterns and the Risk*
326 *of Acute Myocardial Infarction in 52 Countries: Results of the INTERHEART Study*. *Circulation*,
327 2008. **118**(19): p. 1929-1937.
- 328 5. Estruch R, Ros E, Salas-Salvadó J, Covas M-I, Corella D, Arós F, Gómez-Gracia E, Ruiz-
329 Gutiérrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pintó X, Basora J,
330 Muñoz MA, Sorlí JV, Martínez JA, and Martínez-González MA, *Primary prevention of*
331 *cardiovascular disease with a mediterranean diet*. *N Engl J Med*, 2013. **368**(14): p. 1279-
332 1290.
- 333 6. Vlachopoulos C, Aznaouridis K, O'Rourke MF, Safar ME, Baou K, and Stefanadis C, *Prediction*
334 *of cardiovascular events and all-cause mortality with central haemodynamics: a systematic*
335 *review and meta-analysis*. *Eur Heart J*, 2010. **31**(15): p. 1865-1871.
- 336 7. Ben-Shlomo Y, Spears M, Boustred C, May M, Anderson SG, Benjamin EJ, Boutouyrie P,
337 Cameron J, Chen C-H, Cruickshank JK, Hwang S-J, Lakatta EG, Laurent S, Maldonado J,
338 Mitchell GF, Najjar SS, Newman AB, Ohishi M, Pannier B, Pereira T, Vasan RS, Shokawa T,
339 Sutton-Tyrell K, Verbeke F, Wang K-L, Webb DJ, Hansen TW, Zoungas S, McEniery CM,
340 Cockcroft JR, and Wilkinson IB, *Aortic pulse wave velocity improves cardiovascular event*
341 *prediction: an individual participant meta-analysis of prospective observational data from*
342 *17,635 subjects*. *J Am Coll Cardiol*, 2014. **63**(7): p. 636-46.
- 343 8. Lamichhane AP, Liese AD, Urbina EM, Crandell JL, Jaacks LM, Dabelea D, Black MH, Merchant
344 AT, and Mayer-Davis EJ, *Associations of dietary intake patterns identified using reduced rank*
345 *regression with markers of arterial stiffness among youth with type 1 diabetes*. *Eur J Clin*
346 *Nutr*, 2014.

- 347 9. Aatola H, Koivisto T, Hutri-Kähönen N, Juonala M, Mikkilä V, Lehtimäki T, Viikari JSA,
348 Raitakari OT, and Kähönen M, *Lifetime Fruit and Vegetable Consumption and Arterial Pulse*
349 *Wave Velocity in Adulthood / Clinical Perspective*. *Circulation*, 2010. **122**(24): p. 2521-2528.
- 350 10. Dohadwala MM, Holbrook M, Hamburg NM, Shenouda SM, Chung WB, Titas M, Kluge MA,
351 Wang N, Palmisano J, Milbury PE, Blumberg JB, and Vita JA, *Effects of cranberry juice*
352 *consumption on vascular function in patients with coronary artery disease*. *Am J Clin Nutr*,
353 2011. **93**(5): p. 934-940.
- 354 11. Siasos G, Tousoulis D, Kokkou E, Oikonomou E, Kollia M-E, Verveniotis A, Gouliopoulos N,
355 Zisimos K, Plastiras A, Maniatis K, and Stefanadis C, *Favorable Effects of Concord Grape Juice*
356 *on Endothelial Function and Arterial Stiffness in Healthy Smokers*. *Am J Hypertens*, 2014.
357 **27**(1): p. 38-45.
- 358 12. Crichton GE, Elias MF, Dore GA, Abhayaratna WP, and Robbins MA, *Relations Between Dairy*
359 *Food Intake and Arterial Stiffness*. *Hypertension*, 2012. **59**(5): p. 1044-1051.
- 360 13. Recio-Rodriguez J, Gomez-Marcos M, Patino-Alonso M-C, Sanchez A, Agudo-Conde C,
361 Maderuelo-Fernandez J, Garcia-Ortiz L, and Group obotE, *Association between fat amount of*
362 *dairy products with pulse wave velocity and carotid intima-media thickness in adults*. *Nutr J*,
363 2014. **13**(1): p. 37.
- 364 14. Ogedegbe G and Pickering T, *Principles and Techniques of Blood Pressure Measurement*.
365 *Cardiol Clin*, 2010. **28**(4): p. 571-586.
- 366 15. Hwang MH, Yoo JK, Kim HK, Hwang CL, Mackay K, Hemstreet O, Nichols WW, and Christou
367 DD, *Validity and reliability of aortic pulse wave velocity and augmentation index determined*
368 *by the new cuff-based SphygmoCor Xcel*. *J Hum Hypertens*, 2014.
- 369 16. Friedewald WT, Levy RI, and Fredrickson DS, *Estimation of the Concentration of Low-Density*
370 *Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge*. *Clin*
371 *Chem*, 1972. **18**(6): p. 499-502.
- 372 17. Barua AB, Kostic D, and Olson JA, *New simplified procedures for the extraction and*
373 *simultaneous high-performance liquid chromatographic analysis of retinol, tocopherols and*
374 *carotenoids in human serum*. *J Chromatogr*, 1993. **617**(2): p. 257-264.
- 375 18. Benjamini Y and Hochberg Y, *Controlling the False Discovery Rate: A Practical and Powerful*
376 *Approach to Multiple Testing*. *J. Roy. Statist. Soc. Ser. B* 1995. **57**(1): p. 289-300.
- 377 19. Hodge A, Patterson AJ, Brown WJ, Ireland P, and Giles G, *The Anti Cancer Council of Victoria*
378 *FFQ: relative validity of nutrient intakes compared with weighed food records in young to*
379 *middle-aged women in a study of iron supplementation*. *Aust N Z J Public Health*, 2000.
380 **24**(6): p. 576-583.
- 381 20. Xinying PX, Noakes M, and Keogh J, *Can a food frequency questionnaire be used to capture*
382 *dietary intake data in a 4 week clinical intervention trial?* *Asia Pac J Clin Nutr*, 2004. **13**(4): p.
383 318-23.
- 384 21. Schofield W, *Predicting basal metabolic rate, new standards and review of previous work*.
385 *Hum Nutr Clin Nutr*, 1985. **39**(Suppl 1): p. 5-41.
- 386 22. Goldberg GR BA, Jebb SA, Cole TJ, Murgatroyd PR, Coward WA, and AM P, *Critical evaluation*
387 *of energy intake data using fundamental principles of energy physiology: 1. Derivation of cut-*
388 *off limits to identify under-recording*. *Eur J Clin Nutr*, 1991. **45**: p. 569-581.
- 389 23. Livingstone KM, Lovegrove JA, Cockcroft JR, Elwood PC, Pickering JE, and Givens DI, *Does*
390 *Dairy Food Intake Predict Arterial Stiffness and Blood Pressure in Men?: Evidence from the*
391 *Caerphilly Prospective Study*. *Hypertension*, 2013. **61**(1): p. 42-47.
- 392 24. Harding JL, Shaw JE, Peeters A, Guiver T, Davidson S, and Magliano DJ, *Mortality Trends*
393 *Among People With Type 1 and Type 2 Diabetes in Australia: 1997–2010*. *Diabetes Care*,
394 2014. **37**(9): p. 2579-2586.
- 395 25. Spring B, Moller AC, Colangelo LA, Siddique J, Roehrig M, Daviglius ML, Polak JF, Reis JP,
396 Sidney S, and Liu K, *Healthy Lifestyle Change and Subclinical Atherosclerosis in Young Adults:*

- 397 *Coronary Artery Risk Development in Young Adults (CARDIA) Study*. *Circulation*, 2014. **130**(1):
398 p. 10-17.
- 399 26. Ivey KL, Lewis JR, Hodgson JM, Zhu K, Dhaliwal SS, Thompson PL, and Prince RL, *Association*
400 *between yogurt, milk, and cheese consumption and common carotid artery intima-media*
401 *thickness and cardiovascular disease risk factors in elderly women*. *Am J Clin Nutr*, 2011.
402 **94**(1): p. 234-9.
- 403 27. Nestel PJ, Straznicky N, Mellett NA, Wong G, De Souza DP, Tull DL, Barlow CK, Grima MT, and
404 Meikle PJ, *Specific plasma lipid classes and phospholipid fatty acids indicative of dairy food*
405 *consumption associate with insulin sensitivity*. *Am J Clin Nutr*, 2014. **99**(1): p. 46-53.
- 406 28. Guariguata L, Whiting D, Hambleton I, Beagley J, Linnenkamp U, and Shaw J, *Global*
407 *estimates of diabetes prevalence for 2013 and projections for 2035*. *Diabetes research and*
408 *clinical practice*, 2014. **103**(2): p. 137-149.
- 409 29. FitzGerald RJ, Murray BA, and Walsh DJ, *Hypotensive Peptides from Milk Proteins*. *J Nutr*,
410 2004. **134**(4): p. 980S-988S.
- 411 30. Figueroa A, Wong A, Kinsey A, Kalfon R, Eddy W, and Ormsbee MJ, *Effects of Milk Proteins*
412 *and Combined Exercise Training on Aortic Hemodynamics and Arterial Stiffness in Young*
413 *Obese Women With High Blood Pressure*. *Am J Hypertens*, 2014. **27**(3): p. 338-344.
- 414 31. Pal S and Ellis V, *The Chronic Effects of Whey Proteins on Blood Pressure, Vascular Function,*
415 *and Inflammatory Markers in Overweight Individuals*. *Obesity*, 2010. **18**(7): p. 1354-1359.
- 416 32. Lorenzen JK and Astrup A, *Dairy calcium intake modifies responsiveness of fat metabolism*
417 *and blood lipids to a high-fat diet*. *Br J Nutr*, 2011. **105**(12): p. 1823-1831.
- 418 33. Lorenzen JK, Jensen SK, and Astrup A, *Milk minerals modify the effect of fat intake on serum*
419 *lipid profile: results from an animal and a human short-term study*. *Br J Nutr*, 2014. **111**(08):
420 p. 1412-1420.
- 421 34. Crilly MA and McNeill G, *Arterial dysfunction in patients with rheumatoid arthritis and the*
422 *consumption of daily fruits and daily vegetables*. *Eur J Clin Nutr*, 2012. **66**(3): p. 345-352.
- 423 35. Kim OY, Yoe HY, Kim HJ, Park JY, Kim JY, Lee S-H, Lee JH, Lee KP, Jang Y, and Lee JH,
424 *Independent inverse relationship between serum lycopene concentration and arterial*
425 *stiffness*. *Atherosclerosis*, 2010. **208**(2): p. 581-586.
- 426 36. Yeo HY, Kim OY, Lim HH, Kim JY, and Lee JH, *Association of serum lycopene and brachial-*
427 *ankle pulse wave velocity with metabolic syndrome*. *Metabolism*, 2011. **60**(4): p. 537-543.
- 428 37. Nakamura M, Sugiura M, and Aoki N, *High β -carotene and β -cryptoxanthin are associated*
429 *with low pulse wave velocity*. *Atherosclerosis*, 2006. **184**(2): p. 363-369.
- 430 38. Zou Z, Xu X, Huang Y, Xiao X, Ma L, Sun T, Dong P, Wang X, and Lin X, *High serum level of*
431 *lutein may be protective against early atherosclerosis: The Beijing atherosclerosis study*.
432 *Atherosclerosis*, 2011. **219**(2): p. 789-793.
- 433 39. Thies F, Masson LF, Rudd A, Vaughan N, Tsang C, Brittenden J, Simpson WG, Duthie S,
434 Horgan GW, and Duthie G, *Effect of a tomato-rich diet on markers of cardiovascular disease*
435 *risk in moderately overweight, disease-free, middle-aged adults: a randomized controlled*
436 *trial*. *Am J Clin Nutr*, 2012. **95**(5): p. 1013-1022.
- 437 40. Gajendragadkar PR, Hubsch A, Mäki-Petäjä KM, Serg M, Wilkinson IB, and Cheriyan J, *Effects*
438 *of Oral Lycopene Supplementation on Vascular Function in Patients with Cardiovascular*
439 *Disease and Healthy Volunteers: A Randomised Controlled Trial*. *PLoS ONE*, 2014. **9**(6): p.
440 e99070.
- 441 41. Macready AL, George TW, Chong MF, Alimbetov DS, Jin Y, Vidal A, Spencer JP, Kennedy OB,
442 Tuohy KM, Minihane A-M, Gordon MH, Lovegrove JA, and Group ftFS, *Flavonoid-rich fruit*
443 *and vegetables improve microvascular reactivity and inflammatory status in men at risk of*
444 *cardiovascular disease—FLAVURS: a randomized controlled trial*. *Am J Clin Nutr*, 2014.
- 445 42. Vlachopoulos C, Aznaouridis K, and Stefanadis C, *Prediction of Cardiovascular Events and All-*
446 *Cause Mortality With Arterial Stiffness: A Systematic Review and Meta-Analysis*. *J Am Coll*
447 *Cardiol*, 2010. **55**(13): p. 1318-1327.

- 448 43. Sakurai M, Yamakado T, Kurachi H, Kato T, Kuroda K, Ishisu R, Okamoto S, Isaka N, Nakano T,
449 and Ito M, *The relationship between aortic augmentation index and pulse wave velocity: an*
450 *invasive study*. Journal of Hypertension, 2007. **25**(2): p. 391-397
451 10.1097/HJH.0b013e3280115b7c.
- 452 44. Chirinos J, *Arterial Stiffness: Basic Concepts and Measurement Techniques*. Journal of
453 Cardiovascular Translational Research, 2012. **5**(3): p. 243-255.
- 454 45. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B,
455 Vlachopoulos C, Wilkinson I, and Struijker-Boudier H, *Expert consensus document on arterial*
456 *stiffness: methodological issues and clinical applications*. Eur Heart J, 2006. **27**(21): p. 2588-
457 2605.
- 458 46. Lacy PS, O'Brien DG, Stanley AG, Dewar MM, Swales PP, and Williams B, *Increased pulse*
459 *wave velocity is not associated with elevated augmentation index in patients with diabetes*.
460 Journal of Hypertension, 2004. **22**(10): p. 1937-1944.
- 461 47. Jhamnani S, Patel D, Heimlich L, King F, Walitt B, and Lindsay J, *Meta-analysis of the Effects*
462 *of Lifestyle Modifications on Coronary and Carotid Atherosclerotic Burden*. Am J Cardiol, (0).
- 463 48. Hope SA, Meredith IT, Tay D, and Cameron JD, *'Generalizability' of a radial-aortic transfer*
464 *function for the derivation of central aortic waveform parameters*. Journal of hypertension,
465 2007. **25**(9): p. 1812-1820.

466

467 Acknowledgements

468 The authors of this study would like to acknowledge the contributions of study participants and the
469 staff of the University of South Australia. We wish to thank Piyushkumar Mundra for advice on the
470 statistical analysis.

471

472 Funding

473 PJM is supported by a NHMRC senior research fellowship (1042095). This work was supported by the
474 OIS Program of the Victorian Government, Australia. JBK is a Fellow of the South Australian
475 Cardiovascular Research Development Program funded by the Heart Foundation and the
476 Government of South Australia. PMC is supported by a NHMRC Principal Research Fellowship. KSP is
477 funded by an Australian Postgraduate Award + UniSA Rural and Isolated Top-up Scholarship. This
478 research was jointly funded through these fellowships and the University of South Australia.

479